Bicara Therapeutics News and Activities

Bicara Therapeutics is owned by Biocon.

Biocon is one of the...

• Nifty 500;
• TOB Iconic 10,000.

Biocon is a company listed under the stock ticker BIOCON (IN).

Biocon has a direct presence in 2 countries.

Biocon has 3 subsidiaries including Bicara Therapeutics, Biocon Biologics and Syngene.

They are in:

• Biotechnology75%
• Pharmaceuticals25%

Acquisition, funding and merger involving Biocon.

• Bicara Therapeutics is now listed under ticker BCAX. (posted on September 20 2024).

View the org chart displaying its 49 main executives

Most searched biographies at Bicara Therapeutics

• Claire Mazumdar, Chief Executive Officer
• Scott Robertson, Director
• Mike Powell, Chairman of the Board

Popular executive movements at Bicara Therapeutics

• Chris Sarchi has joined the company as Chief Commercial Officer  (posted on June 1 2026).
• Nikki Rohan has joined the company as Vice President, Global Advocacy and Community Engagement  (posted on February 9 2026).
• Aatiyah Paulding has joined the company as Senior Director, People  (posted on October 31 2025).

Popular executive movements at Biocon

• Karthik Sm who was Head of Human Resources, Global Operations and Enabling, becomes Head of Human Resources, India, Malaysia and Emerging Markets  (posted on April 22 2026).
• Kedar Upadhye who is Chief Financial Officer, Combined Business, will be promoted to Chief Financial Officer on Apr. 1, 2026  (posted on March 27 2026).
• Shreehas Tambe who is Chief Executive Officer, Biocon Biologics, will become Director and Chief Executive Officer, Biocon Biologics on Apr. 1, 2026  (posted on March 27 2026).

Click here to view some more movements at Biocon

Create your alert
to follow the executive moves at Bicara Therapeutics.

Biocon has 2,417 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Zymeworks has announced the acquisition of Theravance Biopharma  (posted on June 29 2026).
• Tissium has just announced a $68 Million fundraising (posted on June 29 2026).
• Oblenio Bio has just announced a $62 Million fundraising (posted on June 26 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Bicara Therapeutics

Social media about Bicara Therapeutics

• Bicara Therapeutics on Wikipedia, Google News & Yahoo Finance
• Bicara Therapeutics on LinkedIn, X (Twitter) & YouTube